Thymic epithelial neoplasia: A study of 58 cases

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 197-201

  Elkiran, Emin Tamer ^a   Abali, Huseyin ^a   Aksoy, Sercan ^a   Altundag, Kadri ^a   Erman, Mustafa ^a   Kars, Ayşe ^a   Turker, Alev ^a   Tekuzman, Gulten ^a   Ozisik, Yavuz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Paraneoplastic syndrome; Primary thymic epithelial neoplasms; Radiotherapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NEPHROTIC SYNDROME; OVERALL SURVIVAL; PANCYTOPENIA; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL TIME; THYMUS CANCER; THYMUS SURGERY; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMUS NEOPLASMS;

EID: 36248944105     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698040     Document Type: Article

References (14)

1. Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Onco 1999;17(7):2280-2289.
2. Okumura M, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94(3):624-632.
3. Rios A, et al. Prognostic factors in thymic epithelial neoplasms. Eur J Cardiothorac Surg 2002;21(2):307-313.
4. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48(11):2485-2492.
5. Johnson SB, Eng TY, Giaccone G, Thomas CR, Jr. Thymoma: update for the new millennium. Oncologist 2001;6(3):239-246.
6. Hejna M, Haber I, Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999;85(9):1871-1884.
7. Sonobe S, et al. Clinical usefulness of the WHO histological classification of thymoma. Ann Thorac Cardiovasc Surg 2005;11(6):367-373.
8. Okumura M, et al. Oncological significance of WHO histological thymoma classification. A clinical study based on 286 patients. Jpn J Thorac Cardiovasc Surg 2002;50(5):189-194.
9. Loehrer PJ, Sr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91(11):2010-2015.
10. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14(3):814-820.
11. Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005;17(2):140-146.
12. Henley JD, Cummings OW, Loehrer PJ, Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130(4):222- 224.
13. Altundag K, Morandi P, Altundag O, Yigitbasi OG: Treatment of thymoma and prognostic factors: in regard to Zhu et al. (Int J Radiat Oncol Biol Phys 2004;60:1113-1119). Int J Radiat Oncol Biol Phys 2005;62(3):942.
14. Lardinois D, et al. Prognostic relevance of Masaoka and Muller-Hermelink classification in patients with thymic tumors. Ann Thorac Surg 2000;69(5):1550-1555.